We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. We are advancing a differentiated product pipeline led by our investigational candidate, azetukalner, which is being studied in multiple Phase 3 studies in epilepsy, major depressive disorder, or MDD, and bipolar depr…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$409M
▼ -47.6% YoY
Op. Margin
-4974.27%
ROIC
-37.19%
▼ -17.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$339M
▼ -51.7% YoY
Op. Cash Flow (TTM)
-$338M
▼ -53.9% YoY
Net Debt
-$924M
Net Cash Position
Cash & Equiv.
$931M
5Y CAGR: -25.3%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with XENE
Held by ETFs
XENE is in 50 US ETFs. The largest of them, with XENE's weight in each:
Xenon Pharmaceuticals (XENE) in three numbers
Questions about Xenon Pharmaceuticals
Is Xenon Pharmaceuticals a high-quality business?
Xenon Pharmaceuticals scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from SEC filings. Its best check is net debt at -$924M, and its weakest is return on capital at -37.2%. The Quality tab shows every check against its target.
Does Xenon Pharmaceuticals (XENE) pay a dividend?
No. Xenon Pharmaceuticals (XENE) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 3 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 30 Oct 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in XENE's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing XENE
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.